SHR-1701

Overview

SHR-1701 is an investigational bispecific antibody fusion targeting CD274 (PD-L1) and TGF-β signaling. It is evaluated in nasopharyngeal carcinoma (NPC) and other solid tumors.

Evidence in the corpus

• SHR-1701 bispecific PD-L1×TGF-β antibody fusion listed among investigational dual-target strategies for recurrent/metastatic NPC as part of the bispecific antibody modality class PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.